Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users

Authored by Wayne M Getz, Judith A Hahn, Dennis Wylie, Jesse Dill, Maria S Sanchez, James O Lloyd-Smith, Kimberly Page-Shafer

Date Published: 2009

DOI: 10.1016/j.epidem.2008.10.002

Sponsors: James S. McDonnell Foundation United States National Institutes of Health (NIH)

Platforms: No platforms listed

Model Documentation: Other Narrative

Model Code URLs: Model code not found

Abstract

Background: Hepatitis C virus (HCV) causes significant morbidity and mortality in injecting drug users (IDU) worldwide. HCV vaccine candidates have shown promise for reducing the infectivity of acute infection and averting chronic infection, yet the impact of varying levels of vaccine efficacy and vaccine delivery strategies on the HCV epidemic in IDU has not been explored. Methods: We utilized extensive data on injecting behavior collected in the UFO study of young IDU in San Francisco to construct a stochastic individual-based model that reflects heterogeneous injecting risk behavior, historical HCV trends, and existing information on viral dynamics and vaccine characteristics. Results: Our modeled HCV rate closely paralleled observed HCV incidence in San Francisco, with estimated incidence of 59\% per person year (ppy) early in the epidemic, and 27\% ppy after risk reduction was introduced. Chronic HCV infection, the clinically relevant state of HCV infection that leads to liver disease and hepatocellular cancer, was estimated at 22\% ppy (+/- 3\%) early in the epidemic and 14\% ppy (+/- 2\%) after risk reduction was introduced. We considered several scenarios, and highlight that a vaccine with 50\% to 80\% efficacy targeted to high-risk or sero-negative IDU at a high vaccination rate could further reduce chronic HCV incidence in IDU to 2-7\% ppy 30 years after its introduction. Conclusions: Our results underscore the importance of further efforts to develop both HCV vaccines and optimal systems of delivery to IDU populations. (C) 2008 Elsevier Inc. All rights reserved.

Tags